Anika Therapeutics Company Profile (NASDAQ:ANIK)

About Anika Therapeutics (NASDAQ:ANIK)

Anika Therapeutics logoAnika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Health Care Supplies
  • Symbol: NASDAQ:ANIK
  • CUSIP: 03525510
  • Web: www.anikatherapeutics.com
Capitalization:
  • Market Cap: $705.91 million
  • Outstanding Shares: 14,654,000
Average Prices:
  • 50 Day Moving Avg: $47.52
  • 200 Day Moving Avg: $46.96
  • 52 Week Range: $41.38 - $53.50
P/E:
  • Trailing P/E Ratio: 23.62
  • Foreward P/E Ratio: 28.96
  • P/E Growth: 2.42
Sales & Book Value:
  • Annual Revenue: $104.48 million
  • Price / Sales: 6.87
  • Book Value: $15.70 per share
  • Price / Book: 3.12
Profitability:
  • EBIDTA: $51.71 million
  • Net Margins: 29.81%
  • Return on Equity: 14.29%
  • Return on Assets: 13.23%
Debt:
  • Current Ratio: 17.34%
  • Quick Ratio: 15.76%
Misc:
  • Average Volume: 108,122 shs.
  • Beta: 1.69
  • Short Ratio: 13.7
 

Frequently Asked Questions for Anika Therapeutics (NASDAQ:ANIK)

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc. (NASDAQ:ANIK) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by $0.01. The business had revenue of $23.39 million for the quarter, compared to analyst estimates of $23.89 million. Anika Therapeutics had a net margin of 29.81% and a return on equity of 14.29%. The firm's quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 earnings per share. View Anika Therapeutics' Earnings History.

When will Anika Therapeutics make its next earnings announcement?

Anika Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Anika Therapeutics.

Who are some of Anika Therapeutics' key competitors?

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the folowing people:

  • Charles H. Sherwood Jr, President, Chief Executive Officer, Director
  • Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary
  • Dana M. Alexander, Chief Operating Officer
  • Edward Ahn Ph.D., Chief Technology and Strategy Officer
  • Richard Hague, Chief Commercial Officer
  • Joseph Lyon Bower Ph.D., Lead Independent Director
  • Raymond J. Land, Independent Director
  • Glenn R Larsen Ph.D., Independent Director
  • Jeffrey Scott Thompson, Independent Director
  • Steven E. Wheeler, Independent Director

Who owns Anika Therapeutics stock?

Anika Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include AMI Asset Management Corp (2.11%), BTIM Corp. (1.79%), Fisher Asset Management LLC (0.55%), Capital Management Corp VA (0.42%), Eqis Capital Management Inc. (0.25%) and Bank of Montreal Can (0.14%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Raymond J Land. View Institutional Ownership Trends for Anika Therapeutics.

Who sold Anika Therapeutics stock? Who is selling Anika Therapeutics stock?

Anika Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Capital Management Corp VA, BTIM Corp., New England Research & Management Inc. and Capital One National Association. Company insiders that have sold Anika Therapeutics stock in the last year include Charles H Sherwood, Jeffery S Thompson and Joseph I Bower. View Insider Buying and Selling for Anika Therapeutics.

Who bought Anika Therapeutics stock? Who is buying Anika Therapeutics stock?

Anika Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, Fisher Asset Management LLC, Bank of Montreal Can, State of Alaska Department of Revenue, Eqis Capital Management Inc. and Atria Investments LLC. View Insider Buying and Selling for Anika Therapeutics.

How do I buy Anika Therapeutics stock?

Shares of Anika Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of Anika Therapeutics stock can currently be purchased for approximately $48.95.


MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  57 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  93
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anika Therapeutics (NASDAQ:ANIK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Anika Therapeutics (NASDAQ:ANIK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2016Northland SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/26/2016Barrington ResearchBoost Price TargetOutperform$45.00 -> $49.00N/AView Rating Details
8/27/2015First AnalysisInitiated CoverageEqual -> Equal WeightN/AView Rating Details
(Data available from 7/21/2015 forward)

Earnings

Earnings History for Anika Therapeutics (NASDAQ:ANIK)
Earnings by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Earnings History by Quarter for Anika Therapeutics (NASDAQ ANIK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017$0.44N/AView Earnings Details
5/3/2017Q1 2017$0.38$0.37$23.89 million$23.39 millionViewListenView Earnings Details
2/15/2017Q416$0.53$0.54$27.84 million$28.70 millionViewN/AView Earnings Details
10/26/2016Q316$0.47$0.59$26.60 million$25.79 millionViewListenView Earnings Details
7/27/2016Q216$0.44$0.57$24.75 million$26.60 millionViewListenView Earnings Details
4/27/2016Q116$0.28$0.45$19.26 million$22.30 millionViewListenView Earnings Details
2/24/2016Q415$0.60$0.72$28.19 million$25.60 millionViewListenView Earnings Details
10/28/2015Q315$0.34$0.55$22.36 million$23.70 millionViewListenView Earnings Details
7/29/2015Q215$0.34$0.51$21.65 million$22.90 millionViewListenView Earnings Details
4/28/2015Q115$0.21$0.23$16.20 million$15.50 millionViewListenView Earnings Details
2/25/2015Q414$0.48$0.51$24.60 million$23.30 millionViewListenView Earnings Details
10/29/2014Q314$0.33$0.40$20.33 million$22.10 millionViewListenView Earnings Details
7/30/2014Q214$0.57$0.60$28.20 million$26.27 millionViewListenView Earnings Details
4/29/2014Q114$0.25$0.97$16.03 million$34.00 millionViewN/AView Earnings Details
2/26/2014Q413$0.42$0.44$21.91 million$21.30 millionViewListenView Earnings Details
10/31/2013Q313$0.14$0.33$16.96 million$17.80 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.25$0.40$17.09 million$20.80 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Anika Therapeutics (NASDAQ:ANIK)
2017 EPS Consensus Estimate: $1.85
2018 EPS Consensus Estimate: $1.75
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.34$0.42$0.38
Q2 20172$0.42$0.47$0.45
Q3 20172$0.39$0.42$0.41
Q4 20172$0.62$0.62$0.62
Q1 20182$0.32$0.36$0.34
Q2 20181$0.47$0.47$0.47
Q3 20181$0.44$0.44$0.44
Q4 20181$0.50$0.50$0.50
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anika Therapeutics (NASDAQ:ANIK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Anika Therapeutics (NASDAQ:ANIK)
Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 80.90%
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Insider Trades by Quarter for Anika Therapeutics (NASDAQ:ANIK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Charles H SherwoodCEOSell14,201$50.03$710,476.03View SEC Filing  
5/22/2017Jeffery S ThompsonDirectorSell10,725$47.39$508,257.75View SEC Filing  
11/9/2016Joseph I BowerDirectorSell540$43.39$23,430.60View SEC Filing  
2/25/2016Raymond J LandDirectorSell2,695$43.62$117,555.90View SEC Filing  
2/27/2015Raymond J LandDirectorSell4,621$39.49$182,483.29View SEC Filing  
5/1/2014Charles H SherwoodCEOSell83,780$44.32$3,713,129.60View SEC Filing  
2/28/2014Charles H SherwoodCEOSell200,000$41.70$8,340,000.00View SEC Filing  
8/22/2013John C MoranDirectorSell5,000$24.35$121,750.00View SEC Filing  
8/8/2013Steve E WheelerDirectorSell26,984$23.61$637,092.24View SEC Filing  
8/7/2013Steve E WheelerDirectorSell11,016$27.01$297,542.16View SEC Filing  
8/6/2013Farmaceutici S.P.A. FidiaMajor ShareholderSell1,270,000$24.52$31,140,400.00View SEC Filing  
7/15/2013Charles H SherwoodCEOSell75,000$20.11$1,508,250.00View SEC Filing  
7/9/2013Charles H SherwoodCEOSell49,185$18.06$888,281.10View SEC Filing  
7/5/2013Charles H SherwoodCEOSell34,662$18.01$624,262.62View SEC Filing  
6/19/2013Charles H SherwoodCEOSell1,847$18.00$33,246.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Anika Therapeutics (NASDAQ:ANIK)
Latest Headlines for Anika Therapeutics (NASDAQ:ANIK)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Anticipate Anika Therapeutics Inc. (ANIK) Will Announce Earnings of $0.44 Per Share
www.americanbankingnews.com - July 21 at 10:12 AM
americanbankingnews.com logoZacks: Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - July 21 at 9:18 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Flexion Therapeutics, Ignyta and Anika Therapeutics
finance.yahoo.com - July 18 at 5:22 PM
americanbankingnews.com logoAnika Therapeutics Inc. (ANIK) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - July 18 at 8:16 AM
reuters.com logoBRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc
www.reuters.com - July 17 at 9:19 PM
finance.yahoo.com logoAnika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
finance.yahoo.com - July 17 at 4:16 PM
finance.yahoo.com logoAnika pays former medical chief $350K to thwart possible lawsuit
finance.yahoo.com - July 17 at 12:36 PM
seekingalpha.com logoAnika Therapeutics (ANIK) Presents At Singular Summer Solstice Conference - Slideshow
seekingalpha.com - July 13 at 4:39 PM
finance.yahoo.com logoAnika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : July 12, 2017
finance.yahoo.com - July 12 at 4:24 PM
finance.yahoo.com logoAnika to Issue Second-Quarter 2017 Financial Results and Business Highlights on Wednesday, July 26
finance.yahoo.com - July 12 at 4:24 PM
finance.yahoo.com logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : July 11, 2017
finance.yahoo.com - July 11 at 5:08 PM
finance.yahoo.com logoNew Strong Sell Stocks for July 11th
finance.yahoo.com - July 11 at 5:07 PM
finance.yahoo.com logoETFs with exposure to Anika Therapeutics, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 5:07 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Anika Therapeutics Inc.'s Q2 2017 Earnings (ANIK)
www.americanbankingnews.com - July 10 at 7:36 AM
americanbankingnews.com logoCharles H. Sherwood Sells 14,201 Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) Stock
www.americanbankingnews.com - July 6 at 7:22 PM
finance.yahoo.com logoAnika to Present at the Singular Research Summer Solstice Conference on July 13, 2017
finance.yahoo.com - July 6 at 5:10 PM
americanbankingnews.com logoZacks Investment Research Upgrades Anika Therapeutics Inc. (ANIK) to "Hold"
www.americanbankingnews.com - July 5 at 4:26 PM
americanbankingnews.com logoBrokerages Anticipate Anika Therapeutics Inc. (ANIK) to Post $0.49 EPS
www.americanbankingnews.com - June 28 at 10:28 AM
finanznachrichten.de logoFacial Injectables Market to Reach $17.2 Billion by 2025 - Fueled by Advancements in Facial Rejuvenation Procedures - Research and Markets
www.finanznachrichten.de - June 24 at 2:12 AM
prnewswire.com logoFacial Injectables Market is expected to reach USD 17.2 billion by 2025
www.prnewswire.com - June 20 at 9:09 PM
finance.yahoo.com logoHere Comes a Big Breakout For Alibaba
finance.yahoo.com - June 20 at 4:08 PM
finance.yahoo.com logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ANIK-US : June 19, 2017
finance.yahoo.com - June 19 at 3:39 PM
finance.yahoo.com logoETFs with exposure to Anika Therapeutics, Inc. : June 14, 2017
finance.yahoo.com - June 14 at 3:38 PM
marketwatch.com logoFacial Injectables Market Size Worth $17.2 Billion By 2025: Grand View Research, Inc.
www.marketwatch.com - June 13 at 1:04 PM
finance.yahoo.com logoETFs with exposure to Anika Therapeutics, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 4:47 PM
finance.yahoo.com logoAnika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017
finance.yahoo.com - June 1 at 3:46 PM
finance.yahoo.com logoAnika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
finance.yahoo.com - May 30 at 8:41 PM
finance.yahoo.com logoAnika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
finance.yahoo.com - May 25 at 4:05 PM
americanbankingnews.com logoAnika Therapeutics Inc (ANIK) Director Sells $508,257.75 in Stock
www.americanbankingnews.com - May 23 at 7:47 PM
finance.yahoo.com logoAnika Celebrates 25th Anniversary and Inaugurates Newly Expanded and Consolidated Global Manufacturing Facility in Bedford, Massachusetts
finance.yahoo.com - May 23 at 3:40 PM
finance.yahoo.com logoAnika Announces Publication of Phase III Data Demonstrating the Efficacy and Safety of CINGAL® for the Treatment of Knee Pain Associated with Osteoarthritis
finance.yahoo.com - May 22 at 3:34 PM
americanbankingnews.com logoZacks: Anika Therapeutics Inc (ANIK) Given $52.00 Average Target Price by Brokerages
www.americanbankingnews.com - May 16 at 8:34 PM
finance.yahoo.com logoBiotech Movers: Anika Up on Strong Analyst Ratings
finance.yahoo.com - May 12 at 4:08 PM
americanbankingnews.com logoZacks Investment Research Lowers Anika Therapeutics Inc (ANIK) to Sell
www.americanbankingnews.com - May 8 at 5:28 PM
americanbankingnews.com logoShort Interest in Anika Therapeutics Inc (ANIK) Increases By 0.1%
www.americanbankingnews.com - May 8 at 8:52 AM
americanbankingnews.com logoResearch Analysts Offer Predictions for Anika Therapeutics Inc's Q2 2017 Earnings (ANIK)
www.americanbankingnews.com - May 8 at 8:30 AM
seekingalpha.com logoAnika Therapeutics Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 7 at 11:29 AM
finance.yahoo.com logoEdited Transcript of ANIK earnings conference call or presentation 4-May-17 1:00pm GMT
finance.yahoo.com - May 6 at 1:40 AM
americanbankingnews.com logoAnika Therapeutics Inc (ANIK) Issues Earnings Results
www.americanbankingnews.com - May 4 at 9:00 PM
finance.yahoo.com logoInvestor Network: Anika Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 3:37 PM
finance.yahoo.com logoAnika Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:37 PM
finance.yahoo.com logoAnika posts 1Q profit
finance.yahoo.com - May 3 at 8:37 PM
bizjournals.com logoGlobal Hyaluranoic Acid Raw Material Market expected to be worth 7.25 Billion USD by 2024
www.bizjournals.com - May 3 at 9:31 AM
americanbankingnews.com logoFavorable News Coverage Very Likely to Affect Anika Therapeutics (ANIK) Share Price
www.americanbankingnews.com - May 2 at 2:20 PM
americanbankingnews.com logoAnika Therapeutics Inc (ANIK) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 11:25 AM
finance.yahoo.com logoAnika Therapeutics, Inc. – Value Analysis (NASDAQ:ANIK) : April 28, 2017
finance.yahoo.com - April 28 at 9:33 PM
finance.yahoo.com logoAnika Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ANIK-US : April 27, 2017
finance.yahoo.com - April 27 at 3:56 PM
americanbankingnews.com logoAnika Therapeutics (ANIK) Earning Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 5:14 PM
americanbankingnews.com logoAnika Therapeutics (ANIK) Given News Impact Rating of 0.24
www.americanbankingnews.com - April 21 at 10:17 AM
finance.yahoo.com logoAnika to Issue First-Quarter 2017 Financial Results and Business Highlights on Wednesday, May 3 - Yahoo Finance
finance.yahoo.com - April 20 at 1:34 AM

Social

Chart

Anika Therapeutics (ANIK) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff